Glycation cross-link breakers to increase resistance to enzymatic degradation
US9309304B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 16, 2013 |
| Grant date | Apr 12, 2016 |
| Priority date | — |
| Expiry date | Nov 22, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/78
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to a method to treat a grafts, implant, scaffold, and constructs, including allografts, xenografts, autografts, and prosthetics comprising collagen, with an inhibitor of collagen cross-links and/or advanced glycation endproducts (AGE), in order to alleviate the mechanical weakness induced by the cross-links. The invention also provides for kits for use in the operating theater during autograft, allograft or xenograft procedures, or for preparing allograft, xenografts or prosthetics that have not been already treated prior to packaging. The kit comprises a first agent or agents that inhibit collagen cross-links and/or advanced glycation endproducts, instructions for use, optionally a wash or rinse agent, and a device for containing the graft and first agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.